Compare Organon & Co. Common Stock (OGN) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Royalty Pharma plc Class A Ordinary Shares trades at $59.5 (market cap $26.26B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 7.3× Organon & Co. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.59%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 6 Days on average.
| OGN | RPRX | |
|---|---|---|
Market Cap | $3.61B | $26.26B |
Volume | 1,808,049 | 2,828,067 |
Sector | Health | Health |
52-Week High | $13.81 | $63.96 |
52-Week Low | $5.70 | $36.18 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.03B | $33.49B |
Dividend Yield | 0.58% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Royalty Pharma (RPRX) trades at $56.57, down 2.09% on the day, with a bullish technical signal and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue and net income show steady growth, supported by a high gross profit margin of 89.38%. Analyst consensus is unanimously bullish with a $63.33 price target.
The outlook remains positive given earnings momentum and strategic capital deployment, though risks include biopharma policy shifts and reliance on partner drug performance. The stock offers exposure to a diversified portfolio of blockbuster drugs with minimal operational risk, but investors should monitor upcoming earnings and broader sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
